Synthego competitors

Lucas Nivon is the Co-Founder & CEO at Cyrus Biotechnology. Lucas is trained in computational biophysics and software development.

Sri Kosaraju is an Executive Council and Board Member at Testing for America, Chief Executive Officer at Inscripta Inc, and Audit Chair and Board Member at 10X Genomics and is based in Pleasanton, California. She has worked as President at PENUMBRA INC and Managing Director at JPMorgan Chase &. Sri attended Massachusetts Institute of Technology (MIT) between 1995 and 1999.

I've built my career focused on developing skills in 3 areas: 1) Communication 2) Decision Making 3) Leading People For communication, I've built strategies to be communicated to thousands, been an award winning salesman, and taught college courses. For decision making, I've honed my skills through several years working in strategy and decision support for top companies and been an award winning innovator. For leading people, I've been awarded for leading both strategy/intelligence teams and innovation teams, turned two sales branches from worst to first, and built my own company. The combination of these makes me unique - and I work hard to consistently deliver great outcomes.

Peter McWilliams is a Venture Partner at Sanderling Ventures, Chairman at CalciMedica Inc, and Chairman/Acting CEO at Axikin Pharmaceuticals and is based in San Francisco Bay Area. He has experience at Harkness Pharmaceuticals Inc and Oxford Molecular Group and has worked as Team Member at Cylene Pharmaceuticals, Managing Director at Sanderling Ventures, and Associate at Strategy&. Peter works or has worked as Associate at BOOZ ALLEN HAMILTON HOLDING CORP. He attended Princeton University, Columbia Business School, and University of Cambridge.

Devyn joined Sigilon, an early stage biotechnology company based in Cambridge, MA in March, 2017 as its Chief Operations Officer and Head of Strategy. Prior to this he was head of Business Operations and Strategy at the Medicinal Sciences Division at Pfizer R&D. He was previously at Pfizer's Neusentis Research Unit in the UK from 2011 as Chief Operating Officer responsible for strategy and operations for the unit. Neusentis was focused on developing assets for pain and sensory disorders as well as developing the Regenerative Medicine portfolio. He joined Pfizer's Strategic Management Group in August 2009 supporting the head of Pharmatherapeutics R&D on developing and implementing business strategies and operational plans as well as the Regenerative Medicine Research Unit in its strategic work. Prior to joining Pfizer, Smith was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, he led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Smith worked as a management consultant at Adventis Corporation focused on clients in information intensive companies. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University. He is currently an adjunct faculty member at Northeastern University.